Wednesday, July 8, 2026

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

Bright Minds Biosciences is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker DRUG. Primary therapeutic focus areas include Cocaine-Related Disorders, Cocaine Dependence, Nicotine Depen

19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Clinical program

RAD 001 in combination with Caelyx

Phase 1 · small molecule · Advanced Solid Tumors

RAD 001 in combination with Caelyx for Advanced Solid Tumors is a Phase 1 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Internal code S065RDCX01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
BRIGHT MINDS BIOSCIENCES INC.
Phase
Phase 1
Modality
small_molecule
Indication
Advanced Solid Tumors
Status
active
Trials
1